Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.59 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.59 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | ULK1 | O75385 | 1/20 | 0.44 |
| ▸ | APLNR | P35414 | 2/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14756718 | 1.00 | KDM4E (0.62) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL3824801 | 1.00 | KDM4E (0.62) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL29880648 | 0.98 | KDM4E (0.60) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL15971806 | 0.98 | KDM4E (0.60) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL29880849 | 0.98 | KDM4E (0.60) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL15971577 | 0.98 | KDM4E (0.60) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL14756734 | 0.88 | — | — | |
| SCHEMBL21064299 | 0.88 | — | — | |
| SCHEMBL13485777 | 0.82 | SLC6A1 (0.61) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL20465768 | 0.81 | MAPT (0.63) | KDM4EMAPTKMT2AATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087257-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2020-03-19 | — | — | US | claimed |
| US-10464898-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2019-11-05 | — | — | US | claimed |
| US-20160251311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2016-09-01 | — | — | US | claimed |
| EP-2958894-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatebau KG (DE) | 2015-12-30 | — | — | EP | claimed |
| CN-105102430-A | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPBAU KG | 2015-11-25 | — | — | CN | claimed |
| WO-2014128139-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2014-08-28 | — | — | WO | claimed |
| EP-3663291-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2024-12-18 | — | — | EP | disclosed |
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | MERCK SHARP & DOHME LLC (US) | 2024-08-13 | — | — | US | disclosed |
| US-11897843-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG | 2024-02-13 | — | — | US | disclosed |
| EP-4289819-A2 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | Reuter Chemische Apparatebau e.K. (DE) | 2023-12-13 | — | — | EP | disclosed |
| EP-3653607-B1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPBAU E K (DE) | 2023-10-18 | — | — | EP | disclosed |
| US-20230008387-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | REUTER CHEMISCHE APPARATEBAU KG (DE) | 2023-01-12 | — | — | US | disclosed |
| US-11472770-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | REUTER CHEMISCHE APPARATEBAU KG | 2022-10-18 | — | — | US | disclosed |
| US-20130317031-A1 | Nuclear Transport Modulators And Uses Thereof | Karyopharm Therapeutics Inc. (US) | 2013-11-28 | — | — | US | disclosed |
| WO-2013170068-A2 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| EP-1937688-B1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7507729-B2 | for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230008387-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | NPEPPS, AASDHPPT, DNPEP | KDM4E 1366/4885MAPT 2326/4885KMT2A 2076/4885 |
| US-11472770-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | NPEPPS, AASDHPPT, DNPEP | KDM4E 1366/4885MAPT 2326/4885KMT2A 2076/4885 |
| US-11897843-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | NPEPPS, AASDHPPT, DNPEP | KDM4E 1379/4885MAPT 2418/4885KMT2A 2168/4885 |
| US-12060357-B2 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use | ADORA2A, ADORA2B, ADORA3 | KDM4E 3535/4885MAPT 4545/4885KMT2A 2103/4885 |
| US-20130317031-A1 | Nuclear Transport Modulators And Uses Thereof | XPO1, XPO5, XPOT | KDM4E 2059/4885MAPT 1375/4885KMT2A 2462/4885 |
| US-20200087257-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | NPEPPS, AASDHPPT, DNPEP | KDM4E 1366/4885MAPT 2326/4885KMT2A 2076/4885 |
| US-10464898-B2 | Process for the preparation of enantiomerically enriched 3-aminopiperidine | NPEPPS, AASDHPPT, DNPEP | KDM4E 1395/4885MAPT 2443/4885KMT2A 2141/4885 |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | KDM4E 1207/4885MAPT 348/4885KMT2A 1642/4885 |
| US-20160251311-A1 | PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED 3-AMINOPIPERIDINE | NPEPPS, AASDHPPT, DNPEP | KDM4E 1395/4885MAPT 2443/4885KMT2A 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.